Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for neurological diseases. Its pipeline includes small molecule candidates like bexicaserin, a selective 5-HT2C receptor superagonist for epileptic encephalopathies, and LP659, a CNS-penetrant S1P receptor modulator for neuroinflammatory conditions. The company leverages proprietary GPCR research to create innovative, highly selective treatments addressing unmet medical needs in neurology.
This description was generated via AI from an annual report. Updated about 1 year ago.